144 related articles for article (PubMed ID: 27230486)
1. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
Allegra S; Cusato J; De Francia S; Pirro E; Massano D; Piga A; D'Avolio A
J Pharm Pharmacol; 2017 May; 69(5):525-528. PubMed ID: 27230486
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
Allegra S; De Francia S; Cusato J; Pirro E; Massano D; Piga A; D'Avolio A
J Pharm Pharmacol; 2016 Nov; 68(11):1417-1421. PubMed ID: 27672004
[TBL] [Abstract][Full Text] [Related]
3. Current status of iron overload and chelation with deferasirox.
Choudhry VP; Naithani R
Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
Allegra S; De Francia S; Longo F; Massano D; Cusato J; Arduino A; Pirro E; Piga A; D'Avolio A
Biomed Pharmacother; 2016 Dec; 84():1510-1512. PubMed ID: 27881236
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox: pharmacokinetics and clinical experience.
Galanello R; Campus S; Origa R
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
Yang LP; Keam SJ; Keating GM
Drugs; 2007; 67(15):2211-30. PubMed ID: 17927285
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox AUC efficacy cutoff and role of pharmacogenetics.
Allegra S; Cusato J; De Francia S; Massano D; Piga A; D'Avolio A
Eur J Clin Pharmacol; 2016 Sep; 72(9):1155-7. PubMed ID: 27193993
[No Abstract] [Full Text] [Related]
9. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
Lu MY; Wang N; Wu WH; Lai CW; Kuo PH; Chiang PH; Lin KH; Wu TH
Clin Ther; 2015 Aug; 37(8):1751-60. PubMed ID: 26093827
[TBL] [Abstract][Full Text] [Related]
12. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
Daar S; Pathare A; Nick H; Kriemler-Krahn U; Hmissi A; Habr D; Taher A
Eur J Haematol; 2009 Jun; 82(6):454-7. PubMed ID: 19191863
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
Chandra J; Chaudhary H; Pemde H; Singh V; Dutta AK
Ann Trop Paediatr; 2011; 31(1):47-51. PubMed ID: 21262109
[TBL] [Abstract][Full Text] [Related]
14. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
Karnon J; Tolley K; Vieira J; Chandiwana D
Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
[TBL] [Abstract][Full Text] [Related]
15. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
Unal S; Hazirolan T; Eldem G; Gumruk F
Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
17. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.
Nisbet-Brown E; Olivieri NF; Giardina PJ; Grady RW; Neufeld EJ; Séchaud R; Krebs-Brown AJ; Anderson JR; Alberti D; Sizer KC; Nathan DG
Lancet; 2003 May; 361(9369):1597-602. PubMed ID: 12747879
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
Chirnomas D; Smith AL; Braunstein J; Finkelstein Y; Pereira L; Bergmann AK; Grant FD; Paley C; Shannon M; Neufeld EJ
Blood; 2009 Nov; 114(19):4009-13. PubMed ID: 19724055
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
